ECSP19078239A - Péptido activador de receptor de gip - Google Patents

Péptido activador de receptor de gip

Info

Publication number
ECSP19078239A
ECSP19078239A ECSENADI201978239A ECDI201978239A ECSP19078239A EC SP19078239 A ECSP19078239 A EC SP19078239A EC SENADI201978239 A ECSENADI201978239 A EC SENADI201978239A EC DI201978239 A ECDI201978239 A EC DI201978239A EC SP19078239 A ECSP19078239 A EC SP19078239A
Authority
EC
Ecuador
Prior art keywords
activating peptide
gip
receiver activating
gip receiver
peptide
Prior art date
Application number
ECSENADI201978239A
Other languages
English (en)
Inventor
Mari Adachi
Naoki Nishizawa
Ayumu Niida
Tomoko Morimoto
Yoko Kanematsu
Shiro Takekawa
Taiji Asami
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP19078239A publication Critical patent/ECSP19078239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un compuesto peptídico novedoso que tiene una acción activadora en los receptores de GIP y el uso del compuesto peptídico como un medicamento. Específicamente, se proporcionan un péptido que contiene una secuencia representada por la fórmula (I) o una sal de este y un medicamento que lo comprende. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 (I) en donde cada símbolo es como se definió en la presente.
ECSENADI201978239A 2017-03-31 2019-10-30 Péptido activador de receptor de gip ECSP19078239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017072556 2017-03-31

Publications (1)

Publication Number Publication Date
ECSP19078239A true ECSP19078239A (es) 2019-12-27

Family

ID=62089992

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201978239A ECSP19078239A (es) 2017-03-31 2019-10-30 Péptido activador de receptor de gip

Country Status (21)

Country Link
US (2) US10435445B2 (es)
EP (1) EP3601329A1 (es)
JP (2) JP7175912B2 (es)
KR (1) KR20190134626A (es)
CN (1) CN110709414A (es)
AR (1) AR111346A1 (es)
AU (2) AU2018246553B2 (es)
BR (1) BR112019020438A2 (es)
CA (1) CA3058361A1 (es)
CL (1) CL2019002790A1 (es)
CO (1) CO2019012271A2 (es)
EA (1) EA201992327A1 (es)
EC (1) ECSP19078239A (es)
IL (1) IL269581B1 (es)
JO (2) JOP20180028A1 (es)
MA (1) MA48998A (es)
PE (1) PE20200675A1 (es)
PH (1) PH12019502252A1 (es)
SG (1) SG11201908542QA (es)
TW (1) TWI801373B (es)
WO (1) WO2018181864A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856339A1 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja) * 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
KR20220145888A (ko) * 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
AU2021243671A1 (en) * 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited GIF receptor agonist peptide compounds and uses thereof
EP4126921A2 (en) * 2020-03-25 2023-02-08 Takeda Pharmaceutical Company Limited Qd dosing of gip receptor agonist peptide compounds and uses thereof
JP2023520769A (ja) 2020-03-31 2023-05-19 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト
CA3184717A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonists at glp-1 and gip receptors suitable for oral delivery
AU2022283413B2 (en) * 2021-05-28 2024-05-02 Guangdong Raynovent Biotech Co., Ltd. Preparation and application of polypeptide
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116891522B (zh) * 2022-04-01 2024-05-14 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
WO2023193727A1 (zh) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007028632A2 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
EP2431367A3 (en) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
US8497240B2 (en) * 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
GEP20115241B (en) 2006-10-19 2011-06-10 Takeda Pharmaceutical Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
TW200838515A (en) 2007-02-09 2008-10-01 Takeda Pharmaceutical Fused ring compound
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
KR20110040760A (ko) 2008-06-17 2011-04-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
EP2323678B1 (en) 2008-08-07 2016-03-23 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
EP2320923B1 (en) 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
MX2011001031A (es) 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
WO2011014680A2 (en) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Gastric inhibitory peptide variants and their uses
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
AU2011348202A1 (en) 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
TR201815338T4 (tr) 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
CN104583233B (zh) 2012-06-21 2018-10-23 印第安纳大学研究及科技有限公司 表现出gip受体活性的胰高血糖素的类似物
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
JP6326394B2 (ja) 2015-10-09 2018-05-16 Ｋｙｂ株式会社 ミキサ車の積載量計量装置
WO2017075505A2 (en) 2015-10-28 2017-05-04 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
EP3398961B1 (en) 2015-12-31 2022-06-29 Hanmi Pharm. Co., Ltd. Triple activator activating glucagon, glp-1 and gip receptor
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物

Also Published As

Publication number Publication date
IL269581B1 (en) 2024-02-01
KR20190134626A (ko) 2019-12-04
EP3601329A1 (en) 2020-02-05
AU2022200837A1 (en) 2022-03-03
CL2019002790A1 (es) 2020-05-29
US20180298070A1 (en) 2018-10-18
IL269581A (en) 2019-11-28
JP2020515612A (ja) 2020-05-28
US20200140505A1 (en) 2020-05-07
US10435445B2 (en) 2019-10-08
PH12019502252A1 (en) 2020-06-29
CO2019012271A2 (es) 2020-08-21
PE20200675A1 (es) 2020-06-11
JP7175912B2 (ja) 2022-11-21
TWI801373B (zh) 2023-05-11
AU2018246553A1 (en) 2019-10-17
WO2018181864A1 (en) 2018-10-04
CA3058361A1 (en) 2018-10-04
EA201992327A1 (ru) 2020-02-19
AU2018246553B2 (en) 2021-11-11
JOP20180028A1 (ar) 2019-01-30
US11174301B2 (en) 2021-11-16
TW201841936A (zh) 2018-12-01
BR112019020438A2 (pt) 2020-06-09
JP2023012547A (ja) 2023-01-25
SG11201908542QA (en) 2019-10-30
JOP20190211A1 (ar) 2019-09-15
MA48998A (fr) 2020-02-05
AR111346A1 (es) 2019-07-03
CN110709414A (zh) 2020-01-17

Similar Documents

Publication Publication Date Title
ECSP19078239A (es) Péptido activador de receptor de gip
ECSP15044389A (es) Compuesto peptídico
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
AR094309A1 (es) Compuesto heterociclico fusionado y uso del mismo para el control de plagas
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
NI202000092A (es) Compuestos
ECSP16067137A (es) Compuesto heterocíclico fusionado
CR20150454A (es) Compuestos amida para el tratamiento de vih
ECSP16067163A (es) Compuesto heterocíclico
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
CR20180141A (es) Anticuerpos anti-cd 19 humano humanizados y métodos de utilización
CO2020000134A2 (es) Compuestos cetónicos bicíclicos y métodos de uso de los mismos
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CY1124413T1 (el) Ανταγωνιστες του υποδοχεα cgrp
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
ECSP16096831A (es) Derivados de naftiridinadiona
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
CR20150533A (es) Compuesto peptídico
AR122557A2 (es) Oligonucleótido modificado
TH165161A (th) สารประกอบเพพไทด์
UA112287U (xx) Застосування вінборону для нівелювання антипроліферативного впливу ібупрофену на шлунковий епітелій
TH165161B (th) สารประกอบเพพไทด์